Effect of Cerebral Embolic Protection Devices on CNS Infarction in Surgical Aortic Valve Replacement: A Randomized Clinical Trial
- PMID: 28787505
- PMCID: PMC5808875
- DOI: 10.1001/jama.2017.9479
Effect of Cerebral Embolic Protection Devices on CNS Infarction in Surgical Aortic Valve Replacement: A Randomized Clinical Trial
Abstract
Importance: Stroke is a major complication of surgical aortic valve replacement (SAVR).
Objective: To determine the efficacy and adverse effects of cerebral embolic protection devices in reducing ischemic central nervous system (CNS) injury during SAVR.
Design, setting, and participants: A randomized clinical trial of patients with calcific aortic stenosis undergoing SAVR at 18 North American centers between March 2015 and July 2016. The end of follow-up was December 2016.
Interventions: Use of 1 of 2 cerebral embolic protection devices (n = 118 for suction-based extraction and n = 133 for intra-aortic filtration device) vs a standard aortic cannula (control; n = 132) at the time of SAVR.
Main outcomes and measures: The primary end point was freedom from clinical or radiographic CNS infarction at 7 days (± 3 days) after the procedure. Secondary end points included a composite of mortality, clinical ischemic stroke, and acute kidney injury within 30 days after surgery; delirium; mortality; serious adverse events; and neurocognition.
Results: Among 383 randomized patients (mean age, 73.9 years; 38.4% women; 368 [96.1%] completed the trial), the rate of freedom from CNS infarction at 7 days was 32.0% with suction-based extraction vs 33.3% with control (between-group difference, -1.3%; 95% CI, -13.8% to 11.2%) and 25.6% with intra-aortic filtration vs 32.4% with control (between-group difference, -6.9%; 95% CI, -17.9% to 4.2%). The 30-day composite end point was not significantly different between suction-based extraction and control (21.4% vs 24.2%, respectively; between-group difference, -2.8% [95% CI, -13.5% to 7.9%]) nor between intra-aortic filtration and control (33.3% vs 23.7%; between-group difference, 9.7% [95% CI, -1.2% to 20.5%]). There were no significant differences in mortality (3.4% for suction-based extraction vs 1.7% for control; and 2.3% for intra-aortic filtration vs 1.5% for control) or clinical stroke (5.1% for suction-based extraction vs 5.8% for control; and 8.3% for intra-aortic filtration vs 6.1% for control). Delirium at postoperative day 7 was 6.3% for suction-based extraction vs 15.3% for control (between-group difference, -9.1%; 95% CI, -17.1% to -1.0%) and 8.1% for intra-aortic filtration vs 15.6% for control (between-group difference, -7.4%; 95% CI, -15.5% to 0.6%). Mortality and overall serious adverse events at 90 days were not significantly different across groups. Patients in the intra-aortic filtration group vs patients in the control group experienced significantly more acute kidney injury events (14 vs 4, respectively; P = .02) and cardiac arrhythmias (57 vs 30; P = .004).
Conclusions and relevance: Among patients undergoing SAVR, cerebral embolic protection devices compared with a standard aortic cannula did not significantly reduce the risk of CNS infarction at 7 days. Potential benefits for reduction in delirium, cognition, and symptomatic stroke merit larger trials with longer follow-up.
Trial registration: clinicaltrials.gov Identifier: NCT02389894.
Conflict of interest statement
Figures
Similar articles
-
Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis: The CLEAN-TAVI Randomized Clinical Trial.JAMA. 2016 Aug 9;316(6):592-601. doi: 10.1001/jama.2016.10302. JAMA. 2016. PMID: 27532914 Clinical Trial.
-
Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis: The REPRISE III Randomized Clinical Trial.JAMA. 2018 Jan 2;319(1):27-37. doi: 10.1001/jama.2017.19132. JAMA. 2018. PMID: 29297076 Free PMC article. Clinical Trial.
-
The impact of perioperative stroke and delirium on outcomes after surgical aortic valve replacement.J Thorac Cardiovasc Surg. 2024 Feb;167(2):624-633.e4. doi: 10.1016/j.jtcvs.2022.01.053. Epub 2022 Mar 18. J Thorac Cardiovasc Surg. 2024. PMID: 35483981 Clinical Trial.
-
A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events following transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis.Am J Cardiol. 2013 Sep 15;112(6):850-60. doi: 10.1016/j.amjcard.2013.05.015. Epub 2013 Jun 4. Am J Cardiol. 2013. PMID: 23756547 Review.
-
Role of Cerebral Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement: An Updated Meta-Analysis.J Am Heart Assoc. 2024 Feb 6;13(3):e030587. doi: 10.1161/JAHA.123.030587. Epub 2024 Jan 19. J Am Heart Assoc. 2024. PMID: 38240252 Free PMC article. Review.
Cited by
-
Infarct-related structural disconnection and delirium in surgical aortic valve replacement patients.Ann Clin Transl Neurol. 2024 Feb;11(2):263-277. doi: 10.1002/acn3.51949. Epub 2023 Dec 28. Ann Clin Transl Neurol. 2024. PMID: 38155462 Free PMC article. Clinical Trial.
-
Cognitive Effects of Body Temperature During Hypothermic Circulatory Arrest Trial (GOT ICE): A Randomized Clinical Trial Comparing Outcomes After Aortic Arch Surgery.Circulation. 2024 Feb 27;149(9):658-668. doi: 10.1161/CIRCULATIONAHA.123.067022. Epub 2023 Dec 12. Circulation. 2024. PMID: 38084590 Clinical Trial.
-
Cerebral embolic protection during transcatheter heart interventions.EuroIntervention. 2023 Sep 18;19(7):549-570. doi: 10.4244/EIJ-D-23-00166. EuroIntervention. 2023. PMID: 37720969 Free PMC article. Review.
-
Efficacy and safety of carbon dioxide insufflation for brain protection for patients undergoing planned left-sided open heart valve surgery: protocol for a multicentre, placebo-controlled, blinded, randomised controlled trial (the CO2 Study).BMJ Open. 2023 May 17;13(5):e074221. doi: 10.1136/bmjopen-2023-074221. BMJ Open. 2023. PMID: 37197819 Free PMC article.
-
High versus low blood pressure targets for cardiac surgery while on cardiopulmonary bypass.Cochrane Database Syst Rev. 2022 Nov 30;11(11):CD013494. doi: 10.1002/14651858.CD013494.pub2. Cochrane Database Syst Rev. 2022. PMID: 36448514 Free PMC article. Review.
References
-
- Duke Clinical Research Institute Adult cardiac surgery database: executive summary 10 years. http://www.sts.org/sites/default/files/documents/2016Harvest2_ExecutiveS.... Accessed July 10, 2017.
-
- Grover FL, Vemulapalli S, Carroll JD, et al. . 2016 Annual report of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Ann Thorac Surg. 2017;103(3):1021-1035. - PubMed
-
- Floyd TF, Shah PN, Price CC, et al. . Clinically silent cerebral ischemic events after cardiac surgery. Ann Thorac Surg. 2006;81(6):2160-2166. - PubMed
-
- Alassar A, Soppa G, Edsell M, et al. . Incidence and mechanisms of cerebral ischemia after transcatheter aortic valve implantation compared with surgical aortic valve replacement. Ann Thorac Surg. 2015;99(3):802-808. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
